Comparison · NCT02566369-a92c69e2
CD5789 (Trifarotene) 50μg/g Cream vs Placebo Cream: Investigator Global Assessment (IGA) Success Rate at Week 12
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CD5789 (Trifarotene) 50μg/g Cream vs Placebo Cream: Investigator Global Assessment (IGA) Success Rate at Week 12. Trial comparisons, record NCT02566369-a92c69e2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02566369-a92c69e2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.294 | 0.259 | 0.331 | wilson | |
| Risk in group 2 | 0.195 | 0.165 | 0.228 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0995 | 0.0511 | 0.147 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.51 | 1.23 | 1.85 | log | |
| Odds ratio, group 1 over group 2 | 1.72 | 1.32 | 2.25 | log | |
| Number needed to treat, for one more participant with the outcome on CD5789 (Trifarotene) 50μg/g Cream than on Placebo Cream | 10.1 | 6.79 | 19.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CD5789 (Trifarotene) 50μg/g Cream | CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks. | 180 | 612 | OG000 |
| Group 2 | Placebo Cream | Placebo cream applied once daily for 12 weeks | 116 | 596 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Investigator Global Assessment (IGA) Success Rate at Week 12
- Description
- Number of subjects who achieved an Investigator Global Assessment (IGA) score of 1 (almost clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12.
- Time frame
- From Baseline to Week 12
- Population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris
- NCT number
- NCT02566369
- Phases
- PHASE3
- Conditions
- Acne Vulgaris
- Interventions
- CD5789 (trifarotene) 50μg/g cream, Placebo cream
- Lead sponsor
- Galderma R&D
- Results first posted
- 2019-08-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02566369?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02566369-a92c69e2